We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Byotrol Plc | LSE:BYOT | London | Ordinary Share | GB00B0999995 | ORDS 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.225 | -60.00% | 0.15 | 0.10 | 0.20 | 0.275 | 0.075 | 0.28 | 28,101,349 | 10:34:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Chemicals & Chem Preps, Nec | 4.59M | -1.69M | -0.0037 | -0.41 | 680.84k |
Date | Subject | Author | Discuss |
---|---|---|---|
05/2/2020 11:06 | sold out .... cant keep up with demand . | kcowe | |
05/2/2020 10:57 | Don't talk rubbish. You need to do some research. You must be the thickest guy on this site | bob1995 | |
05/2/2020 07:49 | Massive day ahead once people catch on | letmepass | |
05/2/2020 07:41 | Although you might question whether they think they still need to spend $5m on sales & marketing to get to $20m in sales, given the current climate. They will need to finance working capital and supply chain though, so I presume an investing partner is still desirable, even if the current situation persists. | 1gw | |
05/2/2020 07:27 | "byotrol is currently sold out in the USA due to overwhelming demand from the coronavirus outbreak." Fairly unambiguous statement, that. Can't hurt any negotiations on partnering. | 1gw | |
04/2/2020 22:01 | "Huge slice of luck" Like the huge slice of luck when swine flu struck a decade ago!!! "The significant increase in sales is in part due to the concern regarding swine flu; however it can also be attributed to a greater appreciation of the qualities, efficacy and broad applications of Byotrol. " "We remain confident of the prospects for Byotrol " Distributors & Parners " Healthcare through our relationship with Synergy Health plc in Europe and through distributors in the US * Food and beverage, both through distributors and direct sales * Consumer products through our joint venture, Byotrol Consumer Products Ltd. " Revenues & Cash - placings "with revenues increasing to GBP1,995,375 from GBP387,852 in the same period last year, albeit that some of the increase has related to concerns about swine flu." "cash equivalents and receivables of GBP3,527,232 (2008:GBP1,537,820), partly as a result of the fund raising undertaken in Autumn 2008. " What happened to all those distributors in US, opportunities etc. Oh after a decade we have trials at Target. Oh and Red Cross. :-) Same again, eh!! | sikhthetech | |
04/2/2020 21:56 | Agree. Sad STT!!! | cumnor | |
04/2/2020 21:46 | Love this about you.. And yet you arent invested STT1, but are posting about a stock you arent invested in, so again whats the purpose of your posts? You also post on advfn under a different name posting the same negative posts. So youre either posting for a competitors brand or your trying to short the stock for your employer | letmepass | |
04/2/2020 21:44 | >> 1gw Strangely TLY has done very well since you left having taken your loss and slagged off all the knowledgable posters. A great investment decision. They have even paid a dividend; almost unheard of on Aim! Well done here although the corona virus was a huge slice of luck. | nobbygnome | |
04/2/2020 21:09 | Have the accounts been qualified? " Whilst it may have been possible eventually to obtain a suitable response, the length of time this may have required was indeterminate, and the Board took the decision that the interests of shareholders were best served by publishing the accounts with the consequential qualified audit opinion but resulting in the lifting in the suspension from trading on AIM. " | sikhthetech | |
04/2/2020 20:49 | Trading losses are reducing rapidly and will continue to do so as the formal integration with Medimark concludes at year end. The team is also working on a number of business development and monetisation opportunities that should improve results for the full year. The board remains confident that the Company is on target to deliver sustainable operating profits.We remain very excited about the business outlook for Byotrol." | letmepass | |
04/2/2020 20:33 | Why weren't commercial partners scrambling to partner with Byot like they did last time ? Why did some partners who did, give up, eg Tesco? Byot said in May last year that they were CLOSE to securing a 2nd retailer but now they are searching for a partner... Seems like that potential 2nd retailer pulled out, doesn't it? "We continue our search for a partner for Byotrol24 in the US and have engaged professional advice to assist. Sales at Target continue to increase year on year and month on month, but are not large enough to justify continued, national marketing spend by us even at very small levels. We are now preparing for the trial at Target to finish at the end of March 2020." May 2019: "We are also now close to securing an additional new national retailer trial in the US." TESCO: Question is whether they've managed to find alternative retailer, sign agreements and supplied them before the Coronavirus outbreak settles and is old news.. "Post year end we came to the end of our licence relationship with Robert McBride plc and therefore to supplying surface sprays to Tesco. This was an excellent arrangement for us for many years, but it has now run its course and we expect to generate higher margin opportunities with better brand equity from other consumer initiatives. " | sikhthetech | |
04/2/2020 20:27 | Did I forget to copyright that post stt? Do you not have any original thoughts or even phrasing? That was actually my farewell post (for the time being) on the tly thread. Can we hope that you will also copy the action as well as the words? | 1gw | |
04/2/2020 20:22 | You have a number of posters on this thread who have been in for years, have been wrong for years, and have a huge vested interest in seeing the shareprice recover - and they are not shy at underplaying the risk, overplaying the potential, and playing dirty to try to discredit anyone who dares to present contrarian views and facts from the Company rns'. The ONLY way they can entice newbies in is targeting anyone with contrarian views or those posting facts from the company rns'. Wonder why??? | sikhthetech | |
04/2/2020 17:13 | If the trolls must keep reposting ...a great post by 1GWKeep up at the back, sikhthetech. Where do you think the funds to buy Medimark came from? As I understand it, Byotrol looked at recruiting their own sales staff but came to the conclusion that a better solution was to buy Medimark which came with proven sales & marketing expertise. As you will know from following the Totally plc / Greenbrook Healthcare story, acquisitions often take longer to bring to conclusion than you might think. The earn-out mechanism caused them to silo Medimark for [edit] over 1 year post-acquisition, which must have been frustrating, but perhaps better than what happened with Totally plc where it appears the company fell out with sellers of at least one business over measurement of earn-out, presumably because they integrated too quickly and didn't silo sufficiently.In terms of bigger picture timing, I think they've spent several years focusing mainly on the science and the regulation: getting formulae perfected and then getting formulae and labelling through the various regulatory bodies in the EU and the US. Not much good having a big sales and marketing team if you're still developing the product and labelling. I think the EU target may still be moving to some extent, but they're now in good shape on the regulatory side, especially in the US with receipt of the necessary approvals to allow them to launch byotrol 24 on a trial basis through Target.Ultimately I view byotrol as a technology company which happens to have an FMCG market, rather than as a wholesaler or retailer. As such it has historically focused on development of the product rather than on the sales and marketing, realising a lot of its "revenue" to this point through sales or licensing of its technology/product.T | slicethepie | |
04/2/2020 17:04 | According to their interims, published only a month ago, revenues from consumer segment were only £410k, inc a contribution from Tescos... so consumer revenues about £35k from non-Petcare for 6 months. Even a 10fold increase in consumer sales, ex Petcare, wouldn't add much revenue to Consumer division.... £350k over 6 months or £30k a month... What will happen once the Coronavirus is under control. "Headline H1 revenues in this segment were £0.41m versus £0.45m in H1 2018 (as restated). Petcare remains the largest element of day-to-day sales in consumer, accounting for 92% of consumer sales in the period." | sikhthetech | |
04/2/2020 16:14 | Kcowe, "as monday last week 1 purchased 100 .... in one order .".. really... 100 x 200ml bottles... ;-) Why would you need 100 bottles @ £5.19 (buy one get 1 1/2 price) ??? | sikhthetech | |
04/2/2020 14:23 | Still here ,early days yet .=. over bought at the moment , still out of the bolly bands .. will catch up in a couple of days . then onwards and upwards . | kcowe | |
04/2/2020 13:46 | suddenly gone quiet here soon after the drop after 9.30am!!... I'm sure the p&d will return for another go... | sikhthetech | |
04/2/2020 09:24 | Our mm hope not, happy to take a 10% spread on most buys and sells. | slicethepie | |
04/2/2020 08:58 | Has the circus moved on then? | 1gw | |
03/2/2020 18:45 | Noticed this headline on CNBC's reporting of coronavirus. Puts things into perspective: "The flu has already killed 10,000 across US as world frets over coronavirus" And some backup stats from the CDC, including "between 12,000 – 61,000 deaths annually since 2010" Still, if ever there was a favourable environment in which to close a funding deal for the full-scale commercial launch of byotrol24, I would have thought this has to be it. | 1gw | |
03/2/2020 12:27 | Bargain here still - miles to go | philjeans |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions